| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/25/2010 | WO2009128867A3 Recombinant biologically contained filovirus |
| 03/25/2010 | WO2009121004A3 Neutralizing molecules to viral antigens |
| 03/25/2010 | US20100077498 Compositions and methods for blood-brain barrier delivery in the mouse |
| 03/25/2010 | US20100077497 Ip-10 antibodies and their uses |
| 03/25/2010 | US20100076489 Wound closure material |
| 03/25/2010 | US20100076174 ErbB Interface Peptidomimetics And Methods Of Use Thereof |
| 03/25/2010 | US20100075378 Moraxella catarrhalis basb115 polypeptides |
| 03/25/2010 | US20100074959 Lipid growth factor formulations |
| 03/25/2010 | US20100074945 Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes |
| 03/25/2010 | US20100074939 Harmine compounds for promoting bone growth |
| 03/25/2010 | US20100074925 Antigen specific multi epitope vaccines |
| 03/25/2010 | US20100074924 Membrane protein sm29 of schistosoma mansoni and uses thereof for treating and diagnosing schistosomiasis |
| 03/25/2010 | US20100074923 Purification of bacterial antigens |
| 03/25/2010 | US20100074922 Pneumococcal polysaccharide conjugate vaccine |
| 03/25/2010 | US20100074921 Carrier |
| 03/25/2010 | US20100074920 Peptide vaccine for influenza virus |
| 03/25/2010 | US20100074919 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 03/25/2010 | US20100074918 Vaccine |
| 03/25/2010 | US20100074916 Avian influenza vaccine |
| 03/25/2010 | US20100074915 Chimeric influenza virus-like particles |
| 03/25/2010 | US20100074914 DNA vaccine comprising CTGF-encoding DNA construct and applications thereof |
| 03/25/2010 | US20100074913 Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
| 03/25/2010 | US20100074912 Hila-a24-binding kef-derived peptide |
| 03/25/2010 | US20100074911 Vaccine nebulizers |
| 03/25/2010 | US20100074910 Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment |
| 03/25/2010 | US20100074909 Combinations for the treatment of cancer |
| 03/25/2010 | US20100074908 Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses |
| 03/25/2010 | US20100074907 Methods for Promoting Myelination, Neuronal Survival and Oligodendrocyte Differentiation Via Administration of SP35 or TrkA Antagonists |
| 03/25/2010 | US20100074906 Antibodies Specific for Varicella Zoster Virus |
| 03/25/2010 | US20100074905 Methods for soluble zalpha11 cytokine receptors |
| 03/25/2010 | US20100074904 Specific activation of a regulatory t cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction |
| 03/25/2010 | US20100074903 Novel antibody formulation |
| 03/25/2010 | US20100074902 Methods for human allografting |
| 03/25/2010 | US20100074901 Human anti-amyloid antibodies, compositions, methods and uses |
| 03/25/2010 | US20100074900 Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| 03/25/2010 | US20100074899 Methods for treating conditions associated with masp-2 dependent complement activation |
| 03/25/2010 | US20100074898 Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors |
| 03/25/2010 | US20100074897 Methods and Compositions related to HIF-1 alpha |
| 03/25/2010 | US20100074896 Antagonists of pge2 ep3 receptors |
| 03/25/2010 | US20100074895 Method for detecting and controlling cancer |
| 03/25/2010 | US20100074894 Pharmaceutical composition containing antibodies directed against the herv-w envelope |
| 03/25/2010 | US20100074893 ECM-Complex Antibody Compositions and Methods of Use |
| 03/25/2010 | US20100074892 Monoclonal Antibodies That Neutralize Anthrax Protective Antigen (PA) Toxin |
| 03/25/2010 | US20100074891 Sclerostin and the inhibition of Wnt signaling and bone formation |
| 03/25/2010 | US20100074890 Methods for identifying hcv protease inhibitors |
| 03/25/2010 | US20100074889 4'-allene-substituted nucleoside derivatives |
| 03/25/2010 | US20100074888 Animal having modification in mgat2 gene |
| 03/25/2010 | US20100074887 Methods for Treating and Diagnosing Fibrotic and Fibroproliferative Diseases |
| 03/25/2010 | US20100074886 Ccr2 antagonists for treatment of fibrosis |
| 03/25/2010 | US20100074885 Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase |
| 03/25/2010 | US20100074884 Inhibition of neuronal damage |
| 03/25/2010 | US20100074862 N-sulphonylpyrroles and their use as histone deacetylase inhibitors |
| 03/25/2010 | US20100074846 Campylobacter Vaccines and Methods of use |
| 03/25/2010 | US20100074841 Compositions Against Cancer Antigen LIV-1 and Uses Thereof |
| 03/25/2010 | US20100074840 Anthracycline-Antibody Conjugates for Cancer Therapy |
| 03/25/2010 | CA2774336A1 Genus-wide chlamydial peptide vaccine antigens |
| 03/25/2010 | CA2737758A1 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
| 03/25/2010 | CA2737756A1 Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant |
| 03/25/2010 | CA2737667A1 Targeted binding agents directed to cd105 and uses thereof |
| 03/25/2010 | CA2737455A1 Vaccine adjuvant combinations |
| 03/25/2010 | CA2737378A1 Vaccines containing canine parvovirus genetic variants |
| 03/25/2010 | CA2737074A1 Methods for treating progressive multiple sclerosis |
| 03/25/2010 | CA2736864A1 Stable liquid antibody formulation |
| 03/25/2010 | CA2736604A1 Rabies virus-based recombinant immunocontraceptive compositions and methods of use |
| 03/25/2010 | CA2736511A1 Novel compositions and methods for treating ige-mediated disorders |
| 03/25/2010 | CA2736438A1 Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer |
| 03/25/2010 | CA2736198A1 Novel antibody formulation |
| 03/25/2010 | CA2735900A1 Antibodies directed to dll4 and uses thereof |
| 03/25/2010 | CA2726845A1 Antibodies with altered binding to fcrn and methods of using same |
| 03/25/2010 | CA2725381A1 Nanoemulsion adjuvants |
| 03/24/2010 | EP2166096A2 Moraxella (Branhamella) catarrhalis antigens |
| 03/24/2010 | EP2166019A2 Immunisation against Chlamydia Pneumoniae |
| 03/24/2010 | EP2165715A1 Therapeutic agent for cancer, and method for treatment of cancer |
| 03/24/2010 | EP2165714A1 Humanized antibodies recognizing the beta-amyloid peptide |
| 03/24/2010 | EP2165710A1 Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor |
| 03/24/2010 | EP2164993A2 Methods for production and uses of multipotent cell populations, pluripotent cell populations, differentiated cell populations, and hiv-resistant cell populations |
| 03/24/2010 | EP2164992A1 Compositions and methods for binding lysophosphatidic acid |
| 03/24/2010 | EP2164961A2 Sequence based engineering and optimization of single chain antibodies |
| 03/24/2010 | EP2164874A1 Chimeric and humanized anti-cd44 antibodies that mediate cancer cell cytotoxicity |
| 03/24/2010 | EP2164873A1 Stable igg4 antibodies |
| 03/24/2010 | EP2164872A1 Novel fully human anti-vap-1 monoclonal antibodies |
| 03/24/2010 | EP2164871A2 Anti-cd20 therapeutic compositions and methods |
| 03/24/2010 | EP2164870A1 Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
| 03/24/2010 | EP2164869A2 Antigen-binding proteins targeting s. aureus orf0657n |
| 03/24/2010 | EP2164863A2 Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same |
| 03/24/2010 | EP2164862A1 Clostridial toxin netb |
| 03/24/2010 | EP2164859A2 Methods and compositions involving polymeric immunoglobulin fusion proteins |
| 03/24/2010 | EP2164517A1 Il- 18 and protein kinase r inhibition for the treatment of copd |
| 03/24/2010 | EP2164516A1 Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| 03/24/2010 | EP2164514A2 Antibodies to il-6 and use thereof |
| 03/24/2010 | EP2164513A2 Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
| 03/24/2010 | EP2164511A1 Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations |
| 03/24/2010 | EP2164510A1 Emulsion vaccine compositions comprising antigen and adjuvant in the aqueous phase |
| 03/24/2010 | EP2164333A2 Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic fhv-1 infections, and preventing or treating conjunctivitis |
| 03/24/2010 | EP1881845B1 Nipah virus vaccines |
| 03/24/2010 | EP1755660B1 Method for enhancing or inhibiting insulin-like growth factor-i |
| 03/24/2010 | EP1697403B1 Haemophilus influenzae type iv pili |
| 03/24/2010 | EP1507562B1 Compositions for radioimmunotherapy of brain |
| 03/24/2010 | EP1180938B1 Agents, compositions and methods utilizing the same useful in treating or preventing alzheimer disease |
| 03/24/2010 | EP1075496B1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis |